Search results for "PROFILE"

showing 10 items of 915 documents

PPAR alpha gene variants as predicted performance-enhancing polymorphisms in professional Italian soccer players

2014

Patrizia Proia,1 Antonino Bianco,1 Gabriella Schiera,2 Patrizia Saladino,2 Valentina Contrò,1 Giovanni Caramazza,3 Marcello Traina,1 Keith A Grimaldi,4 Antonio Palma,1 Antonio Paoli5 1Sport and Exercise Sciences Research Unit, 2Department of Biological, Chemical and Pharmaceutical Sciences and Technologies, University of Palermo, Palermo, Italy; 3Regional Sports School of CONI Sicilia, Sicily, Italy; 4Biomedical Engineering Laboratory, Institute of Communication and Computer Systems, National Technical University of Athens, Athens, Greece; 5Department of Biomedical Sciences, University of Padova, Padua, Italy Background: The PPARα gene encodes the peroxisome proliferato…

medicine.medical_specialtyTaqIperoxisome proliferator-activator receptor alpha endurance athletesG allelegene variantsPCR-RFLPchemistry.chemical_compoundBlood serumPolymorphism (computer science)Endurance trainingInternal medicineSettore BIO/10 - BiochimicaGenotypemedicineAlleleOpen Access Journal of Sports MedicineOriginal Researchmedicine.diagnostic_testbusiness.industryEndocrinologychemistryendurance athleteRestriction fragment length polymorphismbusinessLipid profilehuman activities
researchProduct

Menopause symptom management in women with dyslipidemias: An EMAS clinical guide.

2020

Abstract Introduction Dyslipidemias are common and increase the risk of cardiovascular disease. The menopause transition is associated with an atherogenic lipid profile, with an increase in the concentrations of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), apolipoprotein B (apoB) and potentially lipoprotein (a) [Lp(a)], and a decrease in the concentration of high-density lipoprotein cholesterol (HDL-C). Aim The aim of this clinical guide is to provide an evidence-based approach to management of menopausal symptoms and dyslipidemia in postmenopausal women. The guide evaluates the effects on the lipid profile both of menopausal hormone therapy an…

medicine.medical_specialtyTiboloneDydrogesteroneGeneral Biochemistry Genetics and Molecular BiologyVaginal estrogen03 medical and health scienceschemistry.chemical_compound0302 clinical medicineOspemifeneInternal medicinemedicineHumansMass Screening030212 general & internal medicineDyslipidemias030219 obstetrics & reproductive medicinemedicine.diagnostic_testbusiness.industryHypertriglyceridemiaObstetrics and Gynecologymedicine.diseaseLipidsMenopauseEndocrinologychemistrylipids (amino acids peptides and proteins)FemaleMenopauseLipid profilebusinessDyslipidemiamedicine.drugMaturitas
researchProduct

SAT0132 DOES JANUS KINASE INHIBITION INDUCED HYPERLIPIDAEMIA ASSOCIATE WITH AN INCREASE OF AORTIC STIFFNESS IN PATIENTS WITH ARTHRITIS? PRELIMINARY R…

2020

Background:Treatment with Janus Kinase inhibitors (JAK-i) (Tofacitinib, Baricitinib) can cause an increase of serum lipids such as total cholesterol, low- (LDL) and high- (HDL) density lipoproteins in patients with arthritis (1). On the other hand, JAK-i can reduce systemic inflammation and have therefore a beneficial effect on the cardiovascular system of treated patients. However, the effects of JAK-i on the CV system have not been adequately examined. In particular, we are not aware of any ’’real world’’ data concerning CV risk of patients receiving JAK-i treatment.Stiffness of the aortic vasculature is a modifiable, valid and independent surrogate predictor of CV risk and can be measure…

medicine.medical_specialtyTofacitinibmedicine.diagnostic_testbusiness.industryImmunologyArthritisBlood lipidsmedicine.diseaseGeneral Biochemistry Genetics and Molecular BiologyPsoriatic arthritisRheumatologyInternal medicineRheumatoid arthritisArterial stiffnessCardiologyImmunology and AllergyMedicinebusinessLipid profilePulse wave velocityAnnals of the Rheumatic Diseases
researchProduct

Renal function dynamics following co-administration of sacubitril/valsartan and empagliflozin in patients with heart failure and type 2 diabetes

2020

Abstract Aims The aim of this study was to evaluate the safety profile in terms of changes in renal function after co‐treatment with sacubitril/valsartan and empagliflozin in patients with type 2 diabetes (T2D) and heart failure with reduced ejection fraction (HFrEF). Methods and results This multicentre observational analysis included 108 patients with T2D and HFrEF treated with both agents: baseline sacubitril/valsartan (Group A; n = 43), baseline empagliflozin (Group B; n = 42), or both agents initiated simultaneously (Group C; n = 23). The primary endpoint was estimated glomerular filtration rate (eGFR) dynamics across treatment groups. A binary characterization of worsening renal funct…

medicine.medical_specialtyUrologyRenal function030204 cardiovascular system & hematologySacubitril03 medical and health scienceschemistry.chemical_compound0302 clinical medicineHeart failure with reduced ejection fraction (HFrEF)Original Research ArticlesRenal safety profileType 2 diabetes mellitusEmpagliflozinDiseases of the circulatory (Cardiovascular) systemMedicineSGLT2iOriginal Research Article030212 general & internal medicineSacubitril/valsartanCreatinineEjection fractionbusiness.industrymedicine.diseasechemistryValsartanRC666-701Heart failureCardiology and Cardiovascular MedicinebusinessSacubitril Valsartanmedicine.drugRenal function
researchProduct

Estimation of serum lipids in patients with Oral Submucous Fibrosis in India

2014

Objectives: Oral submucous fibrosis (OSMF) is the most prevalent precancerous condition in India. Low levels of lipids serves as a marker and prognostic indicator in the early detection of oral precancerous and cancerous states. In spite of the high prevalence and its potential to undergo malignant transformation, this condition has not widely been investigated with respect to the serum lipid levels. In the present study, an attempt was made to analyze the complete serum lipid profile, total cholesterol (TC), triglycerides (TG), high density lipoprotein (HDL) choleste - rol, low density lipoprotein (LDL) cholesterol and very low density lipoprotein (VLDL) cholesterol in OSMF and controls. M…

medicine.medical_specialtyVery low-density lipoproteinBlood lipidsOdontologíaGastroenterologychemistry.chemical_compoundHigh-density lipoproteinInternal medicinemedicineGeneral DentistryOral Medicine and Pathologymedicine.diagnostic_testCholesterolbusiness.industryResearchmedicine.disease:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludPrecancerous conditionEndocrinologychemistryOral submucous fibrosisLow-density lipoproteinUNESCO::CIENCIAS MÉDICASlipids (amino acids peptides and proteins)businessLipid profile
researchProduct

Indicadores tempranos (0-36 meses) de riesgo de trastorno del espectro autista. Un estudio de revisión.

2018

La prevalencia del trastorno del espectro autista (TEA) ha aumentado de manera muy notable en los últimos años debido fundamentalmente a un aumento del conocimiento sobre el mismo por parte de los profesionales responsables de su identificación y/o diagnóstico.El presente trabajo tiene como objetivo realizar una revisión de los artículos publicados en 2018 que se han propuesto identificar entre los 0 y 36 meses de vida predictores fiables de la posterior aparición del TEA.Se realizó una búsqueda en PsycInfo en la que se localizaron 8 estudios empíricos diseñados para evaluar el poder predictivo de estos indicadores tempranos.En estos estudios se identificaron diferentes síntomas que se cons…

medicine.medical_specialtyVisual perception05 social sciencesPsycINFOSensory profileAudiologySocial stimulimedicine.disease03 medical and health sciences0302 clinical medicineEmpirical researchAutism spectrum disordermedicinePredictive power0501 psychology and cognitive sciencesPsychology030217 neurology & neurosurgery050104 developmental & child psychologyFine motorInternational Journal of Developmental and Educational Psychology. Revista INFAD de Psicología.
researchProduct

Is GH dosing optimal in female patients with adult-onset GH deficiency? An analysis from the NordiNet® International Outcome Study

2017

SummaryObjective To evaluate gender differences in GH dosing, IGF-I and cardiovascular risk markers in adults with GH deficiency (GHD). Design NordiNet® International Outcome Study (NCT00960128), a noninterventional, multicentre study, evaluates the long-term effectiveness and safety of Norditropin® (Novo Nordisk A/S) in the real-life clinical setting. Patients Nondiabetic patients (n = 252; 41·7% female) with adult-onset GHD (age ≥20 years at GH start), ≥4 years’ GH therapy and glycosylated haemoglobin (HbA1c) data at baseline and 4 years. Measurements Effects of gender (adjusted for baseline age and body mass index [BMI], average GH dose, treatment duration and concomitant medication) on …

medicine.medical_specialtyWaistmedicine.diagnostic_testbusiness.industryEndocrinology Diabetes and Metabolism030209 endocrinology & metabolism030204 cardiovascular system & hematology03 medical and health sciencesDose–response relationship0302 clinical medicineEndocrinologyEndocrinologyInternal medicineConcomitantmedicineDosingYoung adultbusinessLipid profileBody mass indexGH DeficiencyClinical Endocrinology
researchProduct

PS-078 Clinical Relevance Of Gamma-glutamyl Transpeptidase In Childhood Obesity

2014

Background and aims Metabolic risk leads to severe comorbidities in obesity. We evaluate the relationship between the values of gamma-glutamyl trans peptidase (GGT), a marker of hepatic involvement, and cardio metabolic risk factors in obese children. Methods A prospective cross-sectional study of 147 children (aged 7 to 16 years) was carried out. Ninety-five children were obese with a body mass index standard deviation score (SDS-BMI) >2 and 52 children were normal weight. Patients with endocrine disease or syndromic obesity were excluded. We have analysed clinical parameters of adiposity (fat mass by bioelectrical impedance, waist and hip circumference), blood pressure, and classical bioc…

medicine.medical_specialtyWaistmedicine.diagnostic_testbusiness.industrymedicine.diseaseObesityChildhood obesitychemistry.chemical_compoundRetinol binding proteinEndocrinologychemistryInternal medicinePediatrics Perinatology and Child HealthMedicineUric acidbusinessLipid profileBody mass indexBioelectrical impedance analysisArchives of Disease in Childhood
researchProduct

Neuropathic pain in cancer: systematic review, performance of screening tools and analysis of symptom profiles.

2017

Background The objectives of this study were to evaluate the methodological quality of rigorous neuropathic pain assessment tools in applicable clinical studies, and determine the performance of screening tools for identifying neuropathic pain in patients with cancer. Methods Systematic literature search identified studies reporting use of Leeds Assessment of Neuropathic Symptoms and Signs (LANSS), Douleur Neuropathique en 4 (DN4) or painDETECT (PDQ) in cancer patients with a clinical diagnosis of neuropathic or not neuropathic pain. Individual patient data were requested to examine descriptor item profiles. Results Six studies recruited a total of 2301 cancer patients of which 1564 (68%) r…

medicine.medical_specialtybusiness.industryConcordanceCancermedicine.disease03 medical and health sciences0302 clinical medicineAnesthesiology and Pain MedicineSymptom profiles030220 oncology & carcinogenesisClinical diagnosisNeoplasmsNeuropathic painPhysical therapyMedicineHumansNeuralgiaScreening toolIn patientbusinessCancer pain030217 neurology & neurosurgeryPain MeasurementBritish journal of anaesthesia
researchProduct

Co-morbid mental health conditions in cancer patients at working age - prevalence, risk profiles, and care uptake

2013

Summary Objective This study examined the prevalence of mental health conditions in cancer patients, the role of socioeconomic position in relation to that, and the use of professional mental health care. Methods Prospective cohort with measurements at the beginning of inpatient treatment (baseline) and 3, 9, and 15 months after baseline using structured clinical interviews based on DSM-IV, questionnaires, and medical records. Results At baseline, 149 out of 502 cancer patients (30%) were diagnosed with a mental health condition. Prevalence was associated with unemployment (odds ratio [OR] 2.0), fatigue (OR 1.9), and pain (OR 1.7). Of those with mental health conditions, 9% saw a psychother…

medicine.medical_specialtybusiness.industryMedical recordCancerExperimental and Cognitive PsychologyOdds ratiomedicine.diseaseCo morbidMental healthRisk profilePsychiatry and Mental healthOncologyMedicineWorking agebusinessPsychiatryProspective cohort studyPsycho-Oncology
researchProduct